Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Entera Bio Ltd. stock logo
ENTX
Entera Bio
$1.87
+0.3%
$1.94
$1.50
$2.79
$85.16M1.69100,980 shs48,438 shs
KALA BIO, Inc. stock logo
KALA
KALA BIO
$15.19
+8.5%
$8.16
$2.92
$15.80
$106.60M-1.81103,743 shs203,971 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.46
+5.5%
$3.63
$2.57
$6.77
$21.39M0.577,874 shs5,060 shs
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$2.34
+1.1%
$2.15
$1.82
$3.09
$95.74M1.69136,783 shs62,461 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Entera Bio Ltd. stock logo
ENTX
Entera Bio
-7.00%-6.06%+2.20%-11.43%-0.53%
KALA BIO, Inc. stock logo
KALA
KALA BIO
-3.31%+14.85%+89.70%+219.63%+135.29%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-2.17%-9.22%-9.84%-2.46%-51.51%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
+0.43%+7.44%+10.53%+3.59%-4.15%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Entera Bio Ltd. stock logo
ENTX
Entera Bio
$1.87
+0.3%
$1.94
$1.50
$2.79
$85.16M1.69100,980 shs48,438 shs
KALA BIO, Inc. stock logo
KALA
KALA BIO
$15.19
+8.5%
$8.16
$2.92
$15.80
$106.60M-1.81103,743 shs203,971 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.46
+5.5%
$3.63
$2.57
$6.77
$21.39M0.577,874 shs5,060 shs
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$2.34
+1.1%
$2.15
$1.82
$3.09
$95.74M1.69136,783 shs62,461 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Entera Bio Ltd. stock logo
ENTX
Entera Bio
-7.00%-6.06%+2.20%-11.43%-0.53%
KALA BIO, Inc. stock logo
KALA
KALA BIO
-3.31%+14.85%+89.70%+219.63%+135.29%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-2.17%-9.22%-9.84%-2.46%-51.51%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
+0.43%+7.44%+10.53%+3.59%-4.15%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Entera Bio Ltd. stock logo
ENTX
Entera Bio
4.00
Strong Buy$10.00436.19% Upside
KALA BIO, Inc. stock logo
KALA
KALA BIO
3.20
Buy$17.2513.60% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NAII, ENTX, ORMP, and KALA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2025
KALA BIO, Inc. stock logo
KALA
KALA BIO
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$30.00
9/3/2025
KALA BIO, Inc. stock logo
KALA
KALA BIO
Lifesci Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/11/2025
Entera Bio Ltd. stock logo
ENTX
Entera Bio
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
7/11/2025
KALA BIO, Inc. stock logo
KALA
KALA BIO
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$12.00
(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Entera Bio Ltd. stock logo
ENTX
Entera Bio
$166K513.02N/AN/A$0.23 per share8.11
KALA BIO, Inc. stock logo
KALA
KALA BIO
$3.89M27.40N/AN/A$2.02 per share7.52
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.19N/AN/A$13.32 per share0.26
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$2M47.87N/AN/A$3.61 per share0.65
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Entera Bio Ltd. stock logo
ENTX
Entera Bio
-$9.54M-$0.26N/AN/AN/A-4,525.11%-77.75%-68.13%11/14/2025 (Estimated)
KALA BIO, Inc. stock logo
KALA
KALA BIO
-$38.51M-$6.79N/AN/AN/AN/A-686.43%-76.81%11/11/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%9/26/2025 (Estimated)
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
-$19.06M-$0.35N/AN/AN/AN/A-19.37%-18.28%11/6/2025 (Estimated)

Latest NAII, ENTX, ORMP, and KALA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
-$0.04-$0.05-$0.01$0.31N/AN/A
8/8/2025Q2 2025
Entera Bio Ltd. stock logo
ENTX
Entera Bio
-$0.11-$0.06+$0.05-$0.06N/AN/A
8/8/2025Q2 2025
KALA BIO, Inc. stock logo
KALA
KALA BIO
-$1.82-$1.71+$0.11-$1.71N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Entera Bio Ltd. stock logo
ENTX
Entera Bio
N/AN/AN/AN/AN/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Entera Bio Ltd. stock logo
ENTX
Entera Bio
N/A
10.47
10.47
KALA BIO, Inc. stock logo
KALA
KALA BIO
3.19
2.10
2.10
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
N/A
26.82
26.81

Institutional Ownership

CompanyInstitutional Ownership
Entera Bio Ltd. stock logo
ENTX
Entera Bio
14.11%
KALA BIO, Inc. stock logo
KALA
KALA BIO
24.61%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
12.73%

Insider Ownership

CompanyInsider Ownership
Entera Bio Ltd. stock logo
ENTX
Entera Bio
10.38%
KALA BIO, Inc. stock logo
KALA
KALA BIO
8.32%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
20.90%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
17.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Entera Bio Ltd. stock logo
ENTX
Entera Bio
2045.66 million40.92 millionOptionable
KALA BIO, Inc. stock logo
KALA
KALA BIO
307.02 million6.44 millionNot Optionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
1041.00 million33.71 millionOptionable

Recent News About These Companies

Oramed Pharmaceuticals Inc. (ORMP) - Yahoo Finance
Oramed Pharm Extends Stock Buyback Program

New MarketBeat Followers Over Time

Media Sentiment Over Time

Entera Bio stock logo

Entera Bio NASDAQ:ENTX

$1.86 +0.01 (+0.27%)
Closing price 03:58 PM Eastern
Extended Trading
$1.86 0.00 (0.00%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

KALA BIO stock logo

KALA BIO NASDAQ:KALA

$15.18 +1.19 (+8.46%)
Closing price 03:59 PM Eastern
Extended Trading
$15.24 +0.06 (+0.40%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.46 +0.18 (+5.52%)
Closing price 03:58 PM Eastern
Extended Trading
$3.32 -0.14 (-4.07%)
As of 04:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

Oramed Pharmaceuticals stock logo

Oramed Pharmaceuticals NASDAQ:ORMP

$2.34 +0.03 (+1.08%)
Closing price 03:58 PM Eastern
Extended Trading
$2.33 0.00 (-0.21%)
As of 04:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.